These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 3502432)
1. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation. Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432 [TBL] [Abstract][Full Text] [Related]
2. [The influence of a biological response modifier on thoracic lymphocytes--a study involving clinical cases and animal experiments]. Hanaue H; Kurosawa T; Miyakawa S; Kitano Y; Nemoto A; Yamoto H; Asagoe T; Shikata J Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1285-9. PubMed ID: 3488025 [TBL] [Abstract][Full Text] [Related]
3. Characterization of recirculating lymphocytes in rheumatoid arthritis patients: selective deficiency of natural killer cells in thoracic duct lymph. Fox RI; Fong S; Tsoukas C; Vaughan JH J Immunol; 1984 Jun; 132(6):2883-7. PubMed ID: 6609962 [TBL] [Abstract][Full Text] [Related]
4. [Oral administration of OK-432 (picibanil). (8th report) clinical application: its immunomodulatory effects on the patients with gastrointestinal cancers]. Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1607-15. PubMed ID: 2809385 [TBL] [Abstract][Full Text] [Related]
5. Effects of oral administration of streptococcal preparation OK-432 on thoracic duct lymphocytes. Hanaue H; Kim DY; Machimura T; Tsukui M; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H Tokai J Exp Clin Med; 1987 Sep; 12(3):159-65. PubMed ID: 3502615 [TBL] [Abstract][Full Text] [Related]
6. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity. Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060 [TBL] [Abstract][Full Text] [Related]
7. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy]. Mitachi Y; Murakawa Y; Okuno M; Kambe M; Kanamaru R; Takahasi H; Wakui A Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):482-8. PubMed ID: 2138871 [TBL] [Abstract][Full Text] [Related]
9. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils. Hayashi Y; Torisu M Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351 [TBL] [Abstract][Full Text] [Related]
10. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770 [TBL] [Abstract][Full Text] [Related]
11. [Experimental study on the antitumor activity of regional lymph nodes during immunotherapy]. Kawata H Nihon Geka Gakkai Zasshi; 1984 Nov; 85(11):1479-89. PubMed ID: 6521727 [TBL] [Abstract][Full Text] [Related]
12. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients. Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458 [TBL] [Abstract][Full Text] [Related]
13. [Significance of human Tr cell in gastric cancer --with special reference to suppressor cell activity]. Itagaki E; Toge T; Tanada M; Hamamoto S; Seto Y; Kohno H; Hattori T Gan To Kagaku Ryoho; 1984 Jan; 11(1):123-9. PubMed ID: 6230053 [TBL] [Abstract][Full Text] [Related]
14. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy]. Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020 [TBL] [Abstract][Full Text] [Related]
15. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311 [TBL] [Abstract][Full Text] [Related]
16. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432]. Kobayashi G Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):68-76. PubMed ID: 2314383 [TBL] [Abstract][Full Text] [Related]
17. [The effect of OK-432 in the treatment of primary lung cancer]. Kishimoto T; Okada K Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430 [TBL] [Abstract][Full Text] [Related]
18. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction]. Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897 [TBL] [Abstract][Full Text] [Related]
19. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. Mazumder A; Grimm EA; Rosenberg SA J Immunol; 1983 Feb; 130(2):958-64. PubMed ID: 6848602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]